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ABSTRACT
DT40 is a B-cell lymphoma-derived avian cell
line widely used to study cell autonomous gene
function because of the high rates with which DNA
constructs are homologously recombined into its
genome. Here, we demonstrate that the power of
the DT40 system can be extended yet further
through the use of RNA interference as an alterna-
tive to gene targeting. We have generated and char-
acterized stable DT40 transfectants in which both
topo 2 genes have been in situ tagged using gene
targeting, and from which the mRNA of both topoi-
somerase 2 isoforms can be conditionally depleted
through the tetracycline-induced expression of
short hairpin RNAs. The cell cycle phenotype of
topo 2-depleted DT40 cells has been compared
with that previously reported for other vertebrate
cells depleted either of topo 2a through gene target-
ing, or depleted of both isoforms simultaneously by
transient RNAi. In addition, the DT40 knockdown
system has been used to explore whether excess
catenation arising through topo 2 depletion is suffi-
cient to trigger the G2 catenation (or decatenation)
checkpoint, proposed to exist in differentiated
vertebrate cells.
INTRODUCTION
DT40 is an avian B-cell line that, because of its hyper-
recombination phenotype, has gained widespread popu-
larity as a model system for studying cell autonomous
gene function (1,2). In this work, we demonstrate
that DT40’s powerful genetic toolbox can be extended
even further through the use of RNA interference
(RNAi) (3) to stably and conditionally KD selected
target gene products.
DT40 cell lines have been established that allow for
the depletion of topoisomerase 2 (topo 2). In vertebrates
there are two isoforms of this enzyme (a and b), encoded
by separate genes (4,5). While topo 2a and 2b are enzy-
matically very similar, the C-terminal domains of the
enzymes diﬀer extensively in amino acid sequence and
post-translational modiﬁcation. The two forms have dis-
tinct patterns of expression: topo 2a, which is cell-cycle
regulated, has levels that are highest in G2/M, and is
essential for the survival of proliferating cells. In contrast,
levels of topo 2b are independent of proliferative status
and it is dispensable at the cellular level (5–14). Topo 2b is
not normally able to compensate for loss of 2a, although it
has been shown that cultured human cells can be rescued
from the lethal eﬀects of 2a depletion by 2b if levels of the
beta isoform are very high (15). Thus, although topo 2a is
likely to be the major form of topo 2 responsible for dec-
atenation and chromosome segregation in proliferating
cells, the contribution of the two isoforms has not yet
been fully established (16,17). While in human HT1080
cells, a conditional null mutant for topo 2a has been
established (18), the ineﬃciency of gene targeting
in most vertebrate cells has restricted the availability
of systems allowing for the depletion of both isoforms
simultaneously. Even in DT40, the establishment of a
cell line conditionally null for both genes would require
ﬁve rounds of gene targeting (because of the presence of
the 2b gene on chromosome 2, which is trisomic in these
cells). Here, we show that it is possible to establish verte-
brate cells from which both isoforms can be conditionally
depleted through stable and inducible short hairpin RNA
(shRNA) expression (19). Although for topo 2, as for
many chicken proteins, antibody availability is limited,
the ease of in situ tagging in DT40 has allowed this possi-
ble limitation to be circumvented.
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In order to validate the use of stable, short hairpin-
activated, gene silencing for gene function studies in
DT40, the cell- cycle phenotype of DT40 cells depleted
either of topo 2a, or of both isoforms simultaneously,
has been compared with that previously reported for
other vertebrate cells [depleted either of topo 2a
(6,18,20) or topo 2b (14,20) through gene targeting, or
depleted of both isoforms by transient RNAi (21,22)]. In
addition, the DT40 KD system has been used to explore
whether excess catenation arising through topo 2 deple-
tion is suﬃcient to trigger the G2 catenation checkpoint,
proposed to exist in diﬀerentiated vertebrate cells (23–26).
MATERIALS AND METHODS
Antibodies
The antibodies and antibody kits used were: anti-tetracy-
cline (Tet)-Repressor rabbit polyclonal antibody TET01
(Mo Bi Tec); anti-GFP (Abcam); anti-Flag M2 monoclo-
nal antibody (Sigma); anti-BrdU MoBu-1 (Abcam);
anti-phospho-Histone H3 (Ser10) (Abcam); Annexin
V-FITC Apoptosis detection reagent (Abcam); anti-
dH2AX(Ser139), mouse monoclonal JBW301 (Upstate);
mouse monoclonal (DM1A) a-tubulin (Abcam) and
mouse monoclonal (AC-15) b-actin (Sigma) (western load-
ing controls). Secondary antibodies used for indirect
immunoﬂuorescence (IF) were: swine anti-rabbit FITC
(Dako) and goat anti-mouse Texas Red (Molecular
Probes).
Cell culture and treatments
DT40 cells were routinely grown in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal bovine serum, 1%
chicken serum, 10–5M b-mercaptoethanol, penicillin,
streptomycin (all from Invitrogen-Gibco), at 378C. To
induce expression from 2TetO2-containing promoters,
cells were grown in medium containing 2.5mg ml–1 doxy-
cycine (dox) (Sigma), with the medium being renewed
every second day. For stable transfection of DNA, cells
were electroporated using standard conditions: 1 107
cells in 800 ml phosphate-buﬀered saline [PBS(A)] using a
BioRad Pulser with 30 mg linearized plasmid DNA at
25 mF and 550V (Sale 2007). After 24 h, the cells
were plated into selective medium in ﬂat-bottomed
96-well dishes. Biochemical selections were as follows:
puromycin (Sigma), 0.5 mg ml–1; blasticidin S (MP
Biomedicals), 30 mgml–1; zeocin (Invitrogen-Gibco),
1mgml–1; G418SO4 (Invitrogen-Gibco), 2mg ml–1.
For transient Cre recombinase expression [allowing for
the excision, and re-use, of ﬂoxed selectable marker cas-
settes, circular (non-linearized) Cre expression plasmid
(pBS185, Invitrogen, (27)] was electroporated as above.
Cells were subcloned by plating into non-selective
medium at limiting dilutions (0.1–10 cells/well) in 96-well
plates; the drug-sensitivity of colonies was tested to
conﬁrm excision.
Small interfering (si) RNA (10–20 mg) (MWG) was tran-
siently transfected into 5 106 DT40 cells using an Amaxa
Nucleofector (Solution T, program B-23) according to the
manufacturer’s recommended protocol.
Cells were irradiated with 4Gy using a Torrex 150
X-ray cabinet. Cells were treated with the following as
appropriate: 1 mM ICRF-193 (EuroMedex), 0.5 mg ml–1
nocodazole (Sigma).
In situ targeting (IST): constructs and transfection
A targeting construct allowing for the introduction of
the Flag epitope at the C-terminus of one topo 2a allele
was generated as follows:
(i) the 50 and 30 homology blocks were PCR ampliﬁed
from genomic DT40 DNA using Takara LA Taq
polymerase and the sequence of cloned fragments
conﬁrmed.
(ii) The 1.3-kb 50 homology block was designed to end
at the stop codon of the open reading frame (ORF),
with a single base change converting the TGA into
TGT. The 50 homology block was cloned into pBSII
SK using KpnI and SalI to generate pBS05T2A.
(iii) Sixty-nucleotide oligos encompassing two copies of
the Flag epitope with SalI and BamHI overhangs,
were designed to produce an in-frame topo 2a:Flag
fusion protein.
(iv) The 1.4-kb 30 homology block, extending from the
stop codon of topo 2a, was PCR ampliﬁed with
BamHI and NotI overhangs.
(v) A three-way ligation was undertaken with
pBS50T2A (linearized using SalI and NotI),
2Flag (SalI–BamHI) and the 30 homology block
(BamHI–NotI).
(vi) Finally a ﬂoxed b-actin promoter-driven puromycin
resistance (puroR) gene was cloned as a BamHI
fragment into the unique BamHI site lying between
the Flag cassette and the 30 homology block.
A targeting construct allowing for the introduction
of enhanced-green ﬂuorescent protein (eGFP) at the
C-terminus of one topo 2b allele was generated using a
similar strategy:
(i) The 2.9-kb 50 homology block was designed to end
at the stop codon of the ORF, with a single base
change converting the TAA into TAC. The 50
homology block was cloned into pBSII SK using
KpnI and SalI to generate pBS05T2B.
(ii) The ORF of eGFP was PCR ampliﬁed with SalI
and BamHI overhangs, designed, upon SalI ligation,
to produce an in-frame topo 2b:eGFP fusion
protein.
(iii) The 1.8-kb 30 homology block, extending from the
stop codon of topo 2b, was PCR ampliﬁed with
BamHI and NotI overhangs.
(iv) A three-way ligation was undertaken with pBS50T2B
(linearized using SalI and NotI), eGFP (SalI–BamHI)
and the 30 homology block (BamHI–NotI).
(v) Finally, a ﬂoxed b-actin promoter-driven puroR
gene was cloned as a BamHI fragment into the
unique BamHI site lying between the eGFP cassette
and the 30 homology block.
For electroporation (BioRad Pulser), constructs were
NotI-linearized. Genomic DNA from puromycin-resistant
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clones was screened by PCR using:
(i) a forward primer lying beyond the 50 homology block:
topo 2a 50-CTGCTTGTCGCTTCTCTTTGTGATG-30
topo 2b 50-CGTAAGCATCAGTTCTTCACTCTC-30
(ii) a reverse primer, based either on eGFP:
50-GTCGTCCTTGAAGAAGATGGTGCG-30
or, on the puroR sequence:
50-GAGATGGGGAGAGTGAAGCAGAAC-30
Selection of target sequences for RNAi
To identify eﬀective targets, potential sequences were
tested using transient transfection of 10–20mg siRNAs
by nucleofection (Amaxa). KD eﬀectiveness was estimated
after 2–3 days by monitoring (i) the eﬀect on cell prolifer-
ation (for topo 2a targets) and (ii) by indirect IF to detect,
as appropriate, the eGFP- or Flag-tagged isoform in ﬁxed
cells. The selected target sequences were then cloned as
60-nt oligos into pSUPERIOR (target sequence in bold):
topo 2a
50 GATCCCC GGAGTTGGTCCTGTTCTCA TTCAAGAGA
TGAGAACAGGACCAACTCC TTTTTA 30
which targets nts 2106–2124 of the ORF.
topo 2b
50 GATCCCC GAAGGAGCCTGGTACTAGA TTCAAGAGA
TCTAGTACCAGGCTCCTTC TTTTTA 30
which targets nts 3939–3957 of the ORF.
Although some alternatively spliced variants of both
isoforms have been identiﬁed, these aﬀect the N-terminal
region of the enzyme (28); the selected target sequences are
predicted to silence all known transcripts.
RNAi expression constructs and transfection
An RNAi expression construct, in which the insert is insu-
lated in order to minimize position eﬀects after integra-
tion, was generated as follows:
(i) Oligonucleotides for shRNA generation were
annealed and cloned, using their BglII and HindIII
overhangs, into pSUPERIOR (Oligoengine).
(ii) A fragment containing two copies of the 250-bp
‘core’ chicken hypersensitive site-4 (HS4) insulator
was released from pNI-CD (29) (kindly provided by
Dr G. Felsenfeld) using KpnI and cloned into the
KpnI site of pBluescript (BS)II SK (Stratagene). A
second 575-bp HS4 core insulator fragment was
isolated from pNI-CD using EcoRI and BamHI
and sticky-end ligated into the same vector, gener-
ating pBSTCF.
(iii) The 300-bp H1 Tet-repressible promoter:shRNA
cassette was removed from pSUPERIOR using
SalI and EcoRI and inserted into the polylinker of
pBSTCF, such that the shRNA expression cassette
is ﬂanked on both sides by tandemly oriented
insulator elements.
(iv) To confer blasticidin resistance, a ﬂoxed b-actin
promoter-driven blasticidin resistance marker (30)
was cloned into the BamHI site of pBSTCF.
Alternatively, for Zeocin-resistance, the HS4 insu-
lated shRNA expression cassette was removed
from pBSTCF using Pvu2 and blunt-ligated into
the EcoRV site of pRSVZeo [kindly provided by
Dr M. Nakanishi (31)].
For electroporation, shRNA expression constructs were
NotI-linearized.
RNA extraction, reverse transcription and real-time PCR
Total RNA was prepared from cells, after 0 and 5 days
doxycycline (dox) exposure, using Trizol, and 5 mg reverse
transcribed using oligo dT (Superscript III First Strand
Synthesis System, Invitrogen). Real-time PCR reactions
were done for topo 2 (a or b) (target genes) and
GAPDH (reference gene) using SYBR Green Supermix
on an IQ5 system (BioRad). Primer sequences used were:
Topo 2a 50-ACTGTGGAGACTGCGTGTC-30 and
50-CTCCGAGACATCAGTGCTAC-30
Topo 2b 50-AGCCTCCAACTGTGGTATC-3 and
50-GAATGTTTGCCACCTGC-30
GAPDH 50-ACCCCAGCAACATCAAATGG-30 and
50-CACCAGTGGACTCCACAACATACT-30
Following validation experiments, the Comparative CT
(CT) method (32) was used to compare topo 2 gene
expression in dox-treated relative to untreated samples
for each cell line.
Tet-inducible KD-resistant (KDR) topo 2a expression:
construct and transfection
Topo 2a cDNA was synthesized from DT40 cells using
the Superscript III CellsDirect cDNA synthesis system
(Invitrogen). cDNA across the ORF was generated by
PCR ampliﬁcation of several smaller sub-fragments
using Accuzyme DNA polymerase (Bioline) and subclon-
ing in pSC-A (StrataClone PCR cloning kit, Stratagene).
The ﬁdelity of each subclone was checked by sequencing,
before ligation into pBSII SK, to generate the complete
ORF. The ﬁdelity of all junctions was again conﬁrmed by
sequencing.
Site-directedmutagenesis, using aQuikChangemultisite-
directed mutagenesis kit (Stratagene), was used to gener-
ate a KDR form of topo 2a through the introduction
of two silent base changes within the shtopo 2a target
sequence (a T to C transition at nt position 2110 of the
ORF and a C to G transversion at nt position 2115)
using the following oligonucleotide (with mutations in
bold):
50 CATCAACAAGGAGCTGGTGCTGTTCTCAAACTC 30.
After conﬁrmation by sequencing, the mutated (KDR)
topo 2a ORF was cloned 30 of eGFP in peGFP-C1 (BD
Biosciences Clontech), as a SalI fragment, so as to encode
an inframe eGFP:topo 2a fusion protein. The chimeric
ORF was removed using NheI and ApaI and placed
under a Tet-inducible CMV promoter in pcDNA4/TO
(Invitrogen). Stable transfectants were isolated by
electroporation of FspI-linearized pcDNA4/TO eGFP:
KDRtopo2a followed by zeocin selection.
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Flow cytometry and cell-cycle analyses
Mitotic index (MI) determination was undertaken by
ﬂow cytometry for detection of phospho Ser10 histone
H3 (33). To monitor progression, through G2 into M,
cells were trapped in M phase by the addition of
0.5mgml1 nocodazole for 8 h. DNA synthesis was mon-
itored through uptake of bromodeoxyuridine (BrdU) and
its detection by ﬂow cytometery using anti-BrdU (34). Cell
death was quantitated by ﬂow cytometry using Annexin
V-FITC Apoptosis detection reagent and propidium
iodide (PI) counterstain, as recommended by the manu-
facturer (Abcam).
Indirect IF and microscopy
Cells were either cytospun (ThermoShandon) onto, or
allowed to loosely attach to, poly-L-lysine-coated slides.
Indirect IF with anti-GFP antibody (1:500) was used to
monitor topo 2b levels in Beaft6.2-derived lines (levels
being too faint to visualize directly), while endogenous
topo 2a levels were monitored using anti-Flag M2 anti-
body (1:500). Cells were ﬁxed in methanol, with antibody
dilutions and washes undertaken in KCM (120mM KCL,
20mM NaCl, 10mM Tris–HCl pH 8.0, 0.5mM EDTA,
0.01% Triton X-100). For the detection of dH2AX cells
were ﬁxed in 4% paraformaldehyde (35).
Secondary antibodies (1:100) were swine anti-rabbit
FITC (Dako), rabbit anti-mouse FITC (Dako) or goat
anti-mouse Texas Red (Molecular Probes). DNA was
counterstained with DAPI (0.5 mg ml–1) and mounted in
Vectorshield (Vector Labs).
Images were captured using the Cytovision system
(Applied Imaging) with a Zeiss Axioskop 2 microscope.
Western blot
Cells were harvested, washed in cold PBS and lysed on ice
in TG lysis buﬀer (20mM Tris (pH 7.5), 137mM NaCl,
1mM EGTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol,
1.5mM MgCl2, 1mM Na3VO4, 1mM PMSF, 20 mM
leupeptin, 10 mg/ml aprotinin and 50mM NaF). Lysates
were cleared by centrifugation at 13 000 g and transferred
to fresh tubes on ice. Total protein was determined by
Bradford assay (Bio-Rad). Equal amounts of cell lysate
were fractionated on SDS–PAGE gels (Hoefer Mighty
Small system) and transferred to methanol soaked
PVDF membranes at 300mA for 1 h in a mini-transblot
apparatus (BioRad). Membranes were incubated in Tris-
buﬀered saline with 0.1% (v/v) Tween-20 (TBST) plus 5%
(w/v) powdered milk (TBST+milk) for at least 1 h
before probing with anti-sera. Primary antibody incuba-
tions were performed in TBST+milk at 48C over-
night followed by three washes of TBST. Anti-GFP
and anti-Flag antibodies were used at 1:2000. Secondary
antibody incubation was performed in TBST+milk
for 1 h at room temperature followed by ﬁve washes
TBST. Antibody-antigen complexes were detected using
ECL according to the manufacturer’s instructions
(Amersham).
Statistical analyses
A two-tailed t-test (unpaired) was used to assess the
statistical signiﬁcance of the observed diﬀerences in cell-
cycle data in Figures 6 and 8.
RESULTS
In situ tagging of both topo 2 isoforms in DT40
To simplify the detection of the two isoforms of chicken
topo 2, a DT40 cell line was established in which one
allele of each had been in situ tagged at its C-terminus.
In addition, this cell line (designated Beaft6.2 and referred
to here after as the parental cell line) expresses
the Tetracycline repressor protein (TetR), allowing for
tet/dox-inducible shRNA expression. The generation
of this cell line was achieved by the following steps
(Figure 1):
(i) one allele of the topo 2b isoform was in situ tagged
with GFP (Figure 2A);
(ii) transient Cre recombinase expression was then used
to remove a ﬂoxed puroR selection cassette;
(iii) a TetR expression construct (pcDNA3/TR,
Invitrogen) was introduced and expression con-
ﬁrmed by western blot of stable transfectants (data
not shown);
(iv) one allele of topo 2a was in situ tagged with the
Flag epitope (Figure 2B). This involved a second
targeting construct, with the ﬂoxed puroR cassette
being re-cycled (30).
Generation of stable DT40 cell lines that can be
conditionally depleted of topo 2
The in situ tagged/tetR-expressing DT40 (parental) line
was stably retroﬁtted for the tet/dox-inducible production
of topo 2a shRNA (Figures 1 and 2C). In this system,
Figure 1. Stepwise-strategy for the generation of stable conditional
topo 2a and 2b knockdown DT40 cell lines.
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expression from the tet/dox-inducible H1 promoter is
repressed by TetR binding to the Tet operator sequence
(2xTetO2) in the absence of tet/dox (36).
The H1/2xTetO2 promoter:shtopo 2a cassette was
cloned between HS4 insulator sequences in order to
allow position site-independent expression (37–39). The
vector, which also contains a b-actin promoter-driven
bsR marker gene, was linearized, transfected into
Beaft6.2 by electroporation and blasticidin-resistant
clones expanded. Ten independent transfectants were
screened at the RNA and protein level, by real-time
PCR and indirect IF, respectively (Figure 3 and data not
shown). Data from the two assays correlated well, validat-
ing the use of the in situ tag for routinely monitoring
topo 2 depletion.
One line displaying robust topo 2a depletion (KD
clone 8, referred to subsequently as aKD) was
re-transfected, using a shtopo 2b expression construct
(Figure 2D) conferring zeocin-resistance. After an initial
screen of several transfectants, one line showing robust
topo 2b depletion was characterized further, with the
KD of both isoforms being conﬁrmed by indirect IF of
ﬁxed cells (Figure 4A) and western blotting (Figure 4B)
(cell line designated abKD).
The effect of topo 2 depletion on cell proliferation
While depletion of topo 2a alone is lethal, with population
growth slowing and then declining over 6 days of dox
exposure, the simultaneous depletion of both isoforms
results in an even more rapid decline in cell number
(Figure 4C). Similar ﬁndings, of a more severe response
following depletion of both isoforms than seen after deple-
tion of 2a alone, have been reported in cultured human
cells (21,22,40).
Rescue of the lethal topo 2a depletion phenotype by
introduction of a KDRtopo 2a transgene
To demonstrate that dox-induced lethality is due to topo
2a depletion, the aKD cell line was engineered to express
KDR topo 2a from a dox-inducible promoter. A CMV/
2xTetO2 promoter-driven GFP:KDRtopo 2a transgene
was introduced and stable zeocin-resistant transfectants
characterized. Although the aKD cells already express a
GFP fusion protein, from the in situ tagged endogenous
topo 2b locus, the levels of this protein are barely detect-
able when visualized directly (i.e. without indirect IF using
anti-GFP antibody) (Figure 5A). Indirect immunoﬂuores-
cence to detect endogenous topo 2a, using anti-Flag
Figure 2. (A) Map showing the 30 region of the Gallus gallus topo 2b genomic locus and the GFP in situ tagging (IST) construct. A homologous
recombination event will result in exon 36, which contains the stop codon, being disrupted, such that the portion encoding the ﬁnal part of the 2b
open reading frame is fused in-frame to sequence encoding eGFP, followed by a stop codon, a ﬂoxed puromycin-resistance gene cassette and
sequence from the 30 homology block. (B) Map showing the 30 region of the chicken topo 2a genomic locus and the Flag IST construct. In the event
of gene targeting, exon 35, which contains the stop codon, will be disrupted such that the protein-encoding portion of the exon is fused in-frame to a
Flag epitope. This is immediately followed by a stop codon, the ﬂoxed puroR marker and sequence from the 30 homology block. In each case,
homologously recombined clones were initially identiﬁed by PCR of genomic DNA ampliﬁed using forward primers (arrowheads) lying 50 to the
homology blocks and with reverse primers based on the GFP or puroR genes. In targeted-tagged clones, the ﬂoxed puroR gene was removed by
transient expression of Cre recombinase. Black boxes represent the position of exons. Exon numbering is based on the Gallus gallus reference
sequence assembly 2.1. Scale bar, 1 kb. (C) Schematic showing the Gallus gallus topo 2a mRNA and its open reading frame (ORF), the various
domains of the protein and the position of the RNAi target sequence (5). (D) Schematic showing the Gallus gallus topo 2b mRNA and ORF, the
various domains of the protein and the position of the RNAi target sequence (5).
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antibody, revealed that upon dox addition, wild-type
(WT) topo2a is depleted (Figure 5A). This is consistent
with shtopo 2a being expressed from the H1/2xTetO2
promoter resulting in targeted degradation of WTtopo
2a mRNA. At the same time, the direct visualization
of GFP in dox-treated cells, revealed levels much higher
than in untreated cells, consistent with the induction of
KDR topo 2a mRNA from the ectopic eGFP:KDRtopo
2a transgene (Figure 5A). Although GFP levels were
variable from cell-to-cell across the clonal population
(an observation made for several independently
derived KDR clones), growth curves revealed that the
induction of GFP:KDRtopo 2a, rescues aKD cells from
dox-lethality, substantially restoring their growth rate
(Figure 5B).
Aneuploidy, polyploidy and cell death in cells depleted
of topo 2
Flow cytometry of the nuclear DNA content by PI stain-
ing revealed a decline in the 2N fraction following topo
Figure 4. (A) Indirect IF of topo 2a and topo 2b in the parental, aKD and abKD cell lines after 6 days dox exposure. Cells were cytospun onto
slides. Topo 2a was detected using anti-Flag antibody (Texas Red) and topo 2b using anti-GFP (FITC). DNA was counterstained using DAPI
(blue). Scale bar, 10 mm. (B) Western blots showing robust knockdown, over 4 days dox exposure, of topo 2a in aKD cells and of both isoforms in
abKD cells. Topo 2a was detected using anti-Flag antibody and 2b using anti-GFP. b-actin was used as a loading control. (C) Growth curves of the
parental (blue), aKD (red) and abKD (green) cell lines grown in the presence (closed circles) and absence (closed squares) of 2.5 mg ml–1 dox for 6
days. Data points represent the mean (SD) based on 3 independent experiments.
Figure 3. (A) Real-time PCR was used to estimate the level of topo 2a mRNA knockdown in several transfectants, ﬁve of which are shown here.
Each bar represents the expression level in cells exposed to dox (5 days) relative to that in untreated cells from the same cell line, calculated using
the Comparative CT (CT) method (mean SD, based on 2 independent experiments). (B) In parallel, the same transfectants were examined
by indirect IF using anti-Flag (FITC) to detect protein from the in situ tagged topo 2a locus. DNA was counterstained with DAPI (blue). Scale
bar, 10 mm.
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2 depletion. While there was no marked eﬀect on the 4N
fraction, a signiﬁcant increase in the accumulation of cells
with a >4N content was detected over 4 days of dox
exposure, especially in cells depleted of both isoforms
(Figure 6A and B). A sub-2N peak was detectable by
Day 4 in cells depleted of both topo 2a and 2b and
Annexin V apoptosis assays conﬁrmed a signiﬁcant
increase in cell death (apoptosis and necrosis) (Figure 6B).
The MI following topo 2 depletion
The MI of the viable cell population was determined by
indirect IF using anti-phospho Ser10 histone H3
(pS10H3), and detection by microscopy and ﬂow cytome-
try (Figure 6B and data not shown). Both approaches
revealed a MI of 2% for all three cell lines. While the
MI increased very slightly in cells exposed to dox over 4
days, this increase was also observed in the parental cells,
suggesting that it is independent of topo 2 depletion.
The distribution of M phase (pS10H3-positive) cells in
prophase, prometaphase/metaphase or anaphase was
examined using microscopy. A slight increase in the frac-
tion of M phase cells in prophase (P 0.05) and corre-
sponding decrease in the numbers in both prometa/
metaphase and (to a lesser extent) anaphase was observed
in both topo 2 depletion lines at Day 4 of dox treatment,
while no change was seen in the parental line (Figure 6C).
This suggests that topo 2 depletion in DT40 cells, while
not aﬀecting the MI, may result in cells spending slightly
longer in the early stages of M phase. Others have
reported similar ﬁndings in HeLa cells (21).
Entry into S phase
To examine whether topo 2-depleted cells continue to
cycle up until cell death, cells were exposed to BrdU for
30min at 0 and 4 days dox exposure. Uptake of BrdU and
the total DNA content of cells were monitored both by
microscopy and ﬂow cytometry using anti-BrdU and PI
(Figure 6B). No diﬀerences in the fraction of cells
synthesizing DNA were detected in any of the cell lines
as a result of dox exposure.
Anaphase bridging and aberrant cytokinesis
Microscopic examination revealed that the majority of
anaphase cells showed extensive chromatin bridging
after topo 2 (a alone, or a plus b) depletion over 3 days
of dox exposure (Figure 7A and B). In addition, DAPI-
staining revealed the occasional appearance of aberrant
teardrop structures in cells depleted of topo 2a, suggestive
of abnormal cytokinesis (Figure 7A and C).
The effect of topo 2 depletion and chemical inhibition on
progression from G2 into M phase
The progression of cells from G2 into M phase was mon-
itored at 0 and 3 days dox exposure. For the last 8 h,
cells were incubated in medium containing nocodazole,
ﬁxed and ﬂow cytometric detection of anti-pS10H3 used
to monitor their accumulation in M phase. A small, but
not signiﬁcant (P> 0.05), decrease in the accumulation of
cells in M phase was detected in all three cell lines after
dox exposure (Figure 8). This suggests that depletion of
topo 2a (or of both isoforms together) does not activate a
G2 checkpoint. This is consistent with the lack of any
change in the MI of the asynchronously growing cell
populations (Figure 6B) and with the lack of any detect-
able eﬀect on levels of DNA damage (as determined
by phosphorylated histone H2AX, gH2AX) (Figure 9A
and B).
For comparison, we examined the eﬀect of chemically
inhibiting topo 2 on progression into M phase. In the
parental cell line Beaft6.2, irrespective of dox exposure,
the topo 2 inhibitor ICRF-193 induces a robust G2
delay, resulting in a 50% decrease in the M phase frac-
tion (Figure 8). This eﬀect is absent in cells depleted of
topo 2, consistent with ICRF-193 acting through topo 2
alone (41). No diﬀerence was seen in the ICRF-193
response between cells depleted of topo 2a alone com-
pared to those depleted of both isoforms together,
Figure 5. (A) Detection of endogenous and ectopically expressed topo 2a in a knockdown-resistant (KDR) derivative of the aKD cell line. The KDR
line was grown in the presence or absence of 2.5 mg ml–1 dox for 8 days, cells ﬁxed and cytopsun onto slides. Endogenous topo 2a was detected
indirectly using anti-Flag (Texas Red). The green signal of the ectopically expressed GFP:KDRtopo2a fusion protein was visualized directly (green).
(Note: the background level of expression from the endogenous GFP-tagged topo 2b locus is extremely faint when visualized directly.) Scale bar,
10 mm. (B) Growth curves of the aKD cell line compared with three KDR clonal derivatives, grown in the presence or absence of 2.5 mg ml–1 dox for
8 days. Data points represent the mean (SD) based on 3 independent experiments.
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suggesting that, in this rapidly proliferating chicken cell
line, ICRF-193 is exerting its eﬀect on G2 progression
primarily through topo 2a (42).
To determine whether topo 2-depleted cells remain
competent to mount a G2 checkpoint delay, at least in
response to DNA damage, cells grown in the presence of
dox for 0 or 3 days were subject to 4Gy of X-irradiation
(IR) and the accumulation of pS10H3-positive cells
over the following 8 h monitored. All three cell lines
show a robust G2 delay in response to IR-induced DNA
damage, which appears unaﬀected by depletion of topo 2
(Figure 8).
DISCUSSION
Where functional analysis demands complete loss of gene
expression gene targeting, to generate knockout alleles, is
the method of choice. However, even in DT40 cells, gene
targeting can be laborious. Moreover if, like topo 2a,
the gene-of-interest (g-o-i) is essential a conditional gene
knockout has to be generated. Typically, this necessitates
the introduction of a repressible rescue construct that
maintains cell viability after gene disruption. Subsequent
repression (or deletion) of the rescue gene then reveals the
full knockout phenotype. Even assuming that cell viability
is maintained through ectopic expression of the rescuing
transgene (which is not always the case), the generation of
conditional knockouts is time consuming. Ideally, any
strategy to study an essential gene in the DT40 cell line
would meet the following criteria: (i) depletion of the gene
product must be conditional; (ii) depletion must proceed
through the endogenous gene, obviating the need for a
rescue construct; and (iii) it should be possible without
the time consuming and costly need to raise an antibody
against the protein-of-interest.
For many investigations, in a wide range of model
systems, the KD of gene products, using the technically
more straightforward approach of RNAi, has been highly
informative. Here, for the ﬁrst time, we demonstrate that
it is possible to use RNAi by means of shRNA to stably
and eﬀectively deplete gene products from DT40 cells,
thus extending the tools available for manipulating this
Figure 6. (A) Flow cytometric analysis of nuclear DNA content of the parental, aKD and abKD cell lines over a 4-day exposure to 2.5 mg ml–1 dox:
x-axis, propidium iodide ﬂuorescence; y-axis, events (total events 30 000). (B) Summary graph of ﬂow cytometric cell cycle data collected from the
parental, aKD and abKD cell lines at 0 (white bars) and 4 days (black) dox. Data represents the mean (SD) based on 3 independent experiments.
(C) Breakdown of M phase cells (into prophase, prometa/metaphase and anaphase) at 0 and 3 days dox based on microscopic examination. Data
points are the mean (SD) of three experiments and are based on >300 pS10H3-positive cells.
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widely used vertebrate cell line. We found that by ﬂanking
the shRNA expression cassette with two tandemly orien-
tated copies of the 250-bp ‘core’ element of the chicken
HS4 insulator (37–39) we were able to generate, with
remarkable ease, stable DT40 cell lines capable
of inducible depletion of topoIIa and topoIIb to a level
suﬃciently low to recapitulate the known knockout
phenotype.
In addition, by using RNAi in conjunction with the in
situ tagging of endogenous genes through gene targeting,
we have developed a strategy for studying gene function
that meets all three of the criteria outlined above. In the
future, we envisage that in situ tagging, with epitopes such
as GFP, will allow any g-o-i to be depleted through the use
of generic shRNA expression constructs. In situ tagging of
all endogenous alleles would be readily achievable through
the recycling of selectable markers and targeting con-
structs, while KD of the selected gene’s product through
its epitope tag, using well-characterized shRNAs, would
remove the need to identify eﬀective, gene-speciﬁc, target
sequences. Furthermore, use of the tet-inducible system for
shRNA induction oﬀers the possibility of simultaneously
inducing expression of a modiﬁed, or mutant, KDR
transgene in the absence of endogenous gene product.
Our strategy has been validated using the type 2 topoi-
somerases, with the phenotype observed following topo 2
depletion being consistent with that described following
both transient KD in human cells (21,22), and the knock-
out of topo 2a in mouse or human cells (6,18,20,40).
Further evidence for the observed phenotype being
due speciﬁcally to the targeted degradation of topo 2
mRNAs is provided by the demonstration that aKD
cells can be rescued from dox-induced lethality by expres-
sion of a KDR-form of topo 2a. Failure to fully restore
Figure 7. (A) Representative examples of anaphase chromatin bridging and teardrop structures suggestive of aberrant cytokineses in aKD and abKD
cells depleted of topo 2 (3 days dox). DNA has been stained with DAPI. Scale bar, 10 mm. (B) Summary graph of the frequency of anaphase bridging
after 3 days dox. Data points are based on three experiments, with a total of >150 anaphases examined. (C) Detection of occasional ‘teardrop’
structures in topo 2-depleted (3 days dox) DT40 cells.
Figure 8. Summary graph of the accumulation of cells staining positive
for the mitotic marker pS10H3 (quantiﬁed by ﬂow cytometry) after 8 h
in the presence of nocodazole, in cultures treated with dox for 0 or 3
days (based on nine independent experiments) (white bars). The impact
of 1 mM ICRF-193 (present throughout the 8-h period with nocodazole)
on progression into M phase is shown alongside (three independent
experiments) (grey bars). To address whether topo 2 depletion has
any eﬀect on the ability of DT40 cells to arrest in G2 in response to
DSBs, cultures were exposed to 4Gy of X-irradiation immediately prior
to nocodazole addition (three independent experiments) (black bars).
Values correspond to the means (SD).
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the starting growth rate under these conditions could be
due to a variety of factors:
(i) the ‘rescuing’ topo 2a is fused at its N-terminus to
GFP, which may compromise functionality;
(ii) the level of topo 2a protein may be suboptimal (too
much, as well as too little, topo 2a protein is known
to be detrimental) (43);
(iii) expression of the KDRtopo 2a protein is uncoupled
from the cell cycle (since the ectopic copy is driven
by a CMV promoter); or
(iv) the shRNAs may exert other, oﬀ-target, eﬀects.
Although, as predicted, depletion of topo 2a alone is
lethal in DT40 cells, the severity of the KD phenotype
was enhanced by depletion of both isoforms simulta-
neously. Similar observations have been reported follow-
ing transient KD of both topo 2 isoforms in HeLa cells
(21,22) and the transient KD of topo 2b from topo
2a-conditionally null mutant HT1080 cells (40), suggesting
that topo 2b contributes to sister chromatid decatenation
in these cell lines.
While topo 2-depleted DT40 cells show extensive ana-
phase chromatin bridging and aberrant cytokineses, the
cells do not arrest at any particular point in the cell
cycle. Instead they continue to cycle, incorporating
BrdU and accumulating in M phase at rates comparable
to normal, becoming increasingly polyploid, with eventual
cell death. Similar observations have been reported for
human HT1080 cells conditionally null mutant for topo
2a (18). Consistent with this lack of any signiﬁcant G2
delay in vertebrate cells, Saccharomyces cerevisiae cells
also progress through S, G2 and M with normal kinetics
in the absence of top2 protein (44). Since topo 2 is respon-
sible for the removal of catenanes arising during DNA
replication, the failure of topo 2 depletion to trigger the
so-called G2 ‘catenation checkpoint’, in either vertebrate
cells or budding yeast, raises questions about the nature of
this checkpoint and whether failed decatenation is, in
itself, suﬃcient to activate it.
The idea of a G2 checkpoint that responds to the pres-
ence of excess catenation emerged largely from observa-
tions made on cells exposed to bisdioxopiperazines, such
as ICRF-193. ICRF-193 traps both DNA duplexes inside
the topo2 dimer, blocking enzyme turnover (45–47) and
has been shown to delay progression through G2 in many
diﬀerentiated cell types (23–26). Since this inhibitor was
originally considered not to induce DSBs, the idea
emerged of a G2 ‘catenation checkpoint’, distinct from
the DNA damage pathways (24). However, recent obser-
vations have raised questions regarding this response.
Firstly, there is uncertainty about what actually triggers
the delay—excess catenation (and if so whether both full-
and/or hemi-catenanes can act as a trigger), or something
else? It has been shown that as well as generating excess
catenanes, inhibition of topo 2 by ICRF-193 traps the
DNA in an immobile clamp altering chromatin topology
(48), while several reports suggest that ICRF-193 does
induce low levels of DSBs (49–51). Secondly, vertebrate
cells normally enter mitosis (and even anaphase) with cate-
nanes and/or hemi-catenanes persisting between sister
chromatids (52–54), suggesting that any G2/M checkpoint
would need to be set to respond only to catenation levels
above a permissible threshold. Since DT40 cells expressing
topo 2 show a robust G2 delay in response to ICRF-193,
possible explanations for the lack of a response following
topo 2 depletion might be that:
(i) the KD mutant cells are so compromised after sev-
eral days exposure to dox they are unable to mount
a delay.
(ii) the ICRF-193-induced delay is triggered by a topo
2-dependent, but catenation-independent, eﬀect of
the inhibitor.
(iii) excess catenation requires topo 2 protein itself to
signal a G2 delay.
(iv) a response occurs, but is masked by the gradual and
asynchronous depletion of topo 2 across the KD
cell population.
While the observation that DT40 cells depleted of topo
2 can still slow down progression into M phase in response
to X-irradiation argues against the ﬁrst point, we are cur-
rently unable to distinguish between the latter possibilities.
The recent development of systems allowing for rapid
depletion of protein from vertebrate cells should allow
the last point to be addressed (55). If no G2 delay is
revealed in such a system then future experiments to
Figure 9. (A) As a measure of levels of DSBs after 3 days dox exposure, parental, aKD and abKD cells were examined by indirect IF for
phosphorylated histone H2AX (gH2AX)-containing foci (FITC) in the cell nuclei. As a positive control, the parental cell line was exposed brieﬂy
to the topo 2 poison etoposide (10 mM, 30min). DNA is counterstained with DAPI. Scale bar, 10 mm. (B) Western blot of gH2AX levels over a 4-day
time course of dox exposure. a-tubulin is the loading control.
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determine whether the expression of catalytically inactive
topo 2 triggers a G2 delay, carried out in a conditional
KD background, should allow any requirement for the
topo 2 protein itself in generating a signal in response to
excess catenation, to be elucidated. In this regard it is
intriguing that budding yeast cells expressing only cataly-
tically inactive top2 have been shown to undergo a stable
G2 arrest, requiring an intact DNA damage checkpoint
(44). Moreover, recent studies have revealed that for an
ICRF-193-induced G2 checkpoint to be triggered in HeLa
cells the presence of topo 2a phosphorylated at Ser1524, is
required (56). Phospho-Ser1524 appears to act as a bind-
ing site for recruitment of the multi-functional Mediator
of DNA damage Checkpoint protein-1 (MDC1) (57).
Where cells expressed only non-phosphorylatible S1524A
topo 2a, ICRF-193 failed to induce a G2 delay, despite
cells being defective in decatenation. Hence, whatever trig-
gers the ICRF-193-associated G2 delay in HeLa cells
(catenation, DSBs, changes in chromatin topology, or
something else) the signal is mediated through topo 2a
Ser1524P. It is possible, therefore, that the accumulation
of excess catenation arising from an absence of topo
2 protein would be unable to activate a G2 check-
point response. Further work is required to elucidate
whether excess DNA catenation can trigger a G2 arrest
of the vertebrate cell cycle and if it can, the mechanism
involved.
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